Allogene Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Allogene Therapeutics has a total shareholder equity of $512.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $642.8M and $130.6M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$448.70m |
| Equity | US$512.23m |
| Total liabilities | US$130.60m |
| Total assets | US$642.84m |
Recent financial health updates
We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
Mar 01
We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
Jun 09We're Hopeful That Allogene Therapeutics (NASDAQ:ALLO) Will Use Its Cash Wisely
Feb 22Allogene Therapeutics (NASDAQ:ALLO) Is In A Good Position To Deliver On Growth Plans
Oct 27Companies Like Allogene Therapeutics (NASDAQ:ALLO) Are In A Position To Invest In Growth
Jul 14We're Hopeful That Allogene Therapeutics (NASDAQ:ALLO) Will Use Its Cash Wisely
Nov 05Recent updates
Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside
Apr 01We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
Mar 01We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
Jun 09We're Hopeful That Allogene Therapeutics (NASDAQ:ALLO) Will Use Its Cash Wisely
Feb 22Allogene Therapeutics (NASDAQ:ALLO) Is In A Good Position To Deliver On Growth Plans
Oct 27Allogene begins phase 2 allogeneic CAR T trial for large B-cell lymphoma candidate
Oct 06An Intrinsic Calculation For Allogene Therapeutics, Inc. (NASDAQ:ALLO) Suggests It's 23% Undervalued
Sep 22Allogene: Possible First Pivotal Study With Allogeneic CAR-T ALLO-501A
Sep 13Allogene Therapeutics GAAP EPS of -$0.52 beats by $0.08, revenue of $0.09M beats by $0.07M
Aug 09Companies Like Allogene Therapeutics (NASDAQ:ALLO) Are In A Position To Invest In Growth
Jul 14Allogene Therapeutics: Multibagger Potential, But Terribly Risky
Jun 24Allogene: Leading The Allogeneic CAR-T Space, Again
Apr 01Allogene: Lifting Of The Clinical Hold Will Be A Major Binary
Jan 12We're Hopeful That Allogene Therapeutics (NASDAQ:ALLO) Will Use Its Cash Wisely
Nov 05Ramifications Of Allogene's Clinical Hold: Possible Sector-Wide Implications
Oct 19Allogene Therapeutics: I Am Buying On The Clinical Hold Dip
Oct 11Financial Position Analysis
Short Term Liabilities: ALLO's short term assets ($459.1M) exceed its short term liabilities ($37.1M).
Long Term Liabilities: ALLO's short term assets ($459.1M) exceed its long term liabilities ($93.5M).
Debt to Equity History and Analysis
Debt Level: ALLO is debt free.
Reducing Debt: ALLO has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ALLO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ALLO has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of 17.8% each year.